miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1
Authors:
- 27 September 2017
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 80 (5) , 973-984
Abstract
MiRNAs are implicated in drug resistance of multiple cancers including non-small cell lung cancer (NSCLC), highlighting the potential of miRNAs as chemoresistance regulators in cancer treatment. This study aims to explore the relationship between miR-181c and chemoresistance of NSCLC cells.Keywords
Funding Information
- Science and Technology Project of Henan Province (172102310158)
This publication has 39 references indexed in Scilit:
- Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemiaMolecular Cytogenetics, 2013
- Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic ChangesPharmacological Reviews, 2012
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- MicroRNA regulation by RNA-binding proteins and its implications for cancerNature Reviews Cancer, 2011
- MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cellsJournal of Biomedical Research, 2010
- Wnt/β-Catenin Signaling: Components, Mechanisms, and DiseasesDevelopmental Cell, 2009
- MicroRNAs modulate the chemosensitivity of tumor cellsMolecular Cancer Therapeutics, 2008
- Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cellCancer Letters, 2007
- MicroRNA biogenesis: coordinated cropping and dicingNature Reviews Molecular Cell Biology, 2005
- WIF1, a component of the Wnt pathway, is down‐regulated in prostate, breast, lung, and bladder cancerThe Journal of Pathology, 2003